Researchers at University of California San Diego School of Medicine and Sanford Burnham Prebys Medical Discovery Institute have discovered that high levels of the protein p62 in human liver samples are strongly associated with cancer recurrence and reduced patient survival.
AstraZeneca announced Wednesday that its recently approved ovarian cancer treatment Lynparza (olaparib) missed a primary endpoint of improving overall survival in patients with advanced gastric cancer.
Early studies of these drugs have demonstrated very impressive remission rates of up to 90 percent.
The company will make available to all hospitals in the U.S. an enhanced rebate program to reduce the price of both heart drugs.
Colombia's government is giving pharmaceutical giant Novartis a few weeks to lower prices on a popular cancer drug or see its monopoly on production of the medicine broken and competition thrown open to generic rivals.
All participants presented intriguing viewpoints for this controversial topic.
The expansive research and translational development collaboration has multiple objectives, but will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system (CNS)
The new structure reflects the importance of oncology to Novartis following the successful integration of the oncology assets acquired from GSK.
Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the main types, is on the increase in the United States.
The researchers are currently looking at how to make the inhaler available to all smokers who would like to use it.
The World Health Organization's chief says the agency is increasingly worried about the Zika virus.
Wal-Mart Stores Inc., the world’s biggest retailer, is joining forces with McKesson Corp., the largest U.S. pharmaceutical distributor, to purchase generic drugs.
Australian scientists may have found a way to stop deadly bacteria from infecting patients.
The financing included the participation of new investors.